EirGenix (TPE:6589) Cyclically Adjusted Revenue per Share: NT$4.58 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6589 EirGenix Inc TPE:6589
58 GF Score
Price NT$44.85
GF Value NT$93.33
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is EirGenix Cyclically Adjusted Revenue per Share?

EirGenix TPE:6589 -3.03% 58 Cyclically Adjusted Revenue per Share is NT$4.58 as of Dec. 2025. GuruFocus rates TPE:6589 with a GF Score™ of 58/100 and a GF Value™ of NT$93.33 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

EirGenix's adjusted revenue per share for the three months ended in Dec. 2025 was NT$1.202. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$4.58 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-19), EirGenix's current stock price is NT$44.85. EirGenix's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was NT$4.58. EirGenix's Cyclically Adjusted PS Ratio of today is 9.79.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of EirGenix was 14.37. The lowest was 9.20. And the median was 11.55.


EirGenix  (TPE:6589) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

EirGenix's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=44.85/4.58
=9.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of EirGenix was 14.37. The lowest was 9.20. And the median was 11.55.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


EirGenix Cyclically Adjusted Revenue per Share Related Terms


EirGenix Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for EirGenix's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EirGenix Cyclically Adjusted Revenue per Share Chart

EirGenix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 4.58

EirGenix Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 4.58

TPE:6589 vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, EirGenix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EirGenix Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EirGenix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where EirGenix's Cyclically Adjusted PS Ratio falls into.


TPE:6589
58GF Score
EirGenix Inc TPE:6589
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EirGenix Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, EirGenix's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=1.202/324.0540*324.0540
=1.202

Current CPI (Dec. 2025) = 324.0540.

EirGenix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.000 233.049 0.000
201412 0.000 234.812 0.000
201512 0.000 236.525 0.000
201606 0.000 241.018 0.000
201612 0.000 241.432 0.000
201706 0.000 244.955 0.000
201709 0.851 246.819 1.117
201712 0.783 246.524 1.029
201803 0.662 249.554 0.860
201806 0.592 251.989 0.761
201809 0.468 252.439 0.601
201812 0.465 251.233 0.600
201903 0.512 254.202 0.653
201906 0.946 256.143 1.197
201909 0.505 256.759 0.637
201912 0.853 256.974 1.076
202003 1.303 258.115 1.636
202006 1.118 257.797 1.405
202009 1.911 260.280 2.379
202012 0.966 260.474 1.202
202103 1.186 264.877 1.451
202106 1.639 271.696 1.955
202109 2.650 274.310 3.131
202112 1.410 278.802 1.639
202203 1.192 287.504 1.344
202206 1.049 296.311 1.147
202209 1.181 296.808 1.289
202212 1.384 296.797 1.511
202303 0.710 301.836 0.762
202306 0.456 305.109 0.484
202309 0.700 307.789 0.737
202312 1.492 306.746 1.576
202403 0.718 312.332 0.745
202406 0.804 314.175 0.829
202409 0.814 315.301 0.837
202412 0.963 315.605 0.989
202503 0.601 319.799 0.609
202506 0.765 322.561 0.769
202509 0.759 324.800 0.757
202512 1.202 324.054 1.202

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$4.58 mean?
EirGenix (TPE:6589) has a Cyclically Adjusted Revenue per Share of NT$4.58 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on EirGenix and its competitors.
Is EirGenix's Cyclically Adjusted Revenue per Share too high?
EirGenix's current Cyclically Adjusted Revenue per Share is NT$4.58. Overall, EirGenix has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EirGenix's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
EirGenix's Cyclically Adjusted Revenue per Share of NT$4.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on EirGenix and its competitors. EirGenix's current Cyclically Adjusted Revenue per Share is NT$4.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EirGenix stock overvalued right now?
Based on GuruFocus' analysis, EirGenix (TPE:6589) is currently considered Possible Value Trap. The stock's GF Value™ is NT$93.33, compared to a current price of NT$44.85 — trading 51.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$4.58. EirGenix's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For EirGenix (TPE:6589), the current Cyclically Adjusted Revenue per Share is NT$4.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is EirGenix (TPE:6589) Overvalued in 2026?

Based on GuruFocus' analysis, EirGenix stock appears to be undervalued. The current stock price of NT$44.85 is trading 51.9% below its estimated GF Value™ of NT$93.33. GuruFocus considers EirGenix to be Possible Value Trap.

Key valuation signals for TPE:6589:

  • Cyclically Adjusted Revenue per Share: NT$4.58
  • GF Value™: NT$93.33 vs. price of NT$44.85 (51.9% below fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the TPE:6589 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


EirGenix Business Description

Address No. 101, Lane 169, Kangning Street, Xizhi District, New Taipei, TWN, 22180
EirGenix Inc is engaged in the research and development of biosimilars and new drugs, as well as biopharmaceutical contract development and manufacturing services, which included cell line construction platforms, process development platforms, analytical science and protein identification. Its products include CRM197 CARRIER PROTEIN, PRODUCT PIPELINE, COVID-19 ANTIGEN RAPID TEST. The revenue is derived from biopharmaceutical contract development and manufacturing services, sales of authorization and cooperative development, and sales of goods. Geographically, it operates in Japan, Taiwan, USA and Canada, Mainland China, Hong Kong, and Macao, and Europe, Others.
58GF Score

Get the complete analysis for TPE:6589

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$44.85
Price
NT$93.33
GF Value